Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin lymphoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Selinexor (selinexor)

Snippet

Sponsor: Jennifer Woyach | Conditions: Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2025-06-10